Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · Real-Time Price · USD
0.2060
-0.0140 (-6.36%)
At close: Mar 28, 2025, 4:00 PM
0.2102
+0.0042 (2.04%)
Pre-market: Mar 31, 2025, 9:21 AM EDT
Adaptimmune Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 91.14 | 143.99 | 108.03 | 149.95 | 56.88 | Upgrade
|
| Short-Term Investments | 60.47 | 2.95 | 96.57 | 219.63 | 311.34 | Upgrade
|
| Cash & Short-Term Investments | 151.61 | 146.94 | 204.61 | 369.58 | 368.22 | Upgrade
|
| Cash Growth | 3.18% | -28.18% | -44.64% | 0.37% | 311.22% | Upgrade
|
| Accounts Receivable | 1.45 | 0.82 | 7.44 | 0.75 | 0.14 | Upgrade
|
| Other Receivables | 14.53 | 46.1 | 30.65 | 33.26 | 20.95 | Upgrade
|
| Receivables | 15.98 | 46.92 | 38.09 | 34.01 | 21.09 | Upgrade
|
| Inventory | 7.38 | 1.33 | 1.28 | 0.75 | 2.09 | Upgrade
|
| Prepaid Expenses | 10.03 | 9.95 | 9.47 | 9.04 | 6.31 | Upgrade
|
| Other Current Assets | 3.17 | 2.41 | 1.93 | 2.08 | 0.44 | Upgrade
|
| Total Current Assets | 188.17 | 207.55 | 255.37 | 415.46 | 398.15 | Upgrade
|
| Property, Plant & Equipment | 51.22 | 71.71 | 71.54 | 51.37 | 46.66 | Upgrade
|
| Other Intangible Assets | 3.88 | 0.33 | 0.44 | 1 | 1.73 | Upgrade
|
| Other Long-Term Assets | 2.7 | 3.03 | 1.57 | 1.72 | 4.6 | Upgrade
|
| Total Assets | 245.96 | 282.62 | 328.92 | 469.55 | 451.14 | Upgrade
|
| Accounts Payable | 8.69 | 8.13 | 4.75 | 8.11 | 6.39 | Upgrade
|
| Accrued Expenses | 30.9 | 28.85 | 29.06 | 29.58 | 27.03 | Upgrade
|
| Current Portion of Leases | 4.71 | 5.38 | 2.73 | 2.32 | 2.77 | Upgrade
|
| Current Income Taxes Payable | - | 1.4 | - | - | - | Upgrade
|
| Current Unearned Revenue | 12.3 | 28.97 | 23.52 | 22.2 | 2.83 | Upgrade
|
| Other Current Liabilities | 7.93 | 0.05 | 4.44 | 0.33 | 0.05 | Upgrade
|
| Total Current Liabilities | 64.53 | 72.79 | 64.5 | 62.54 | 39.07 | Upgrade
|
| Long-Term Debt | 50.24 | - | - | - | - | Upgrade
|
| Long-Term Leases | 19.26 | 19.85 | 20.35 | 23.15 | 20.94 | Upgrade
|
| Long-Term Unearned Revenue | 95.82 | 149.06 | 160.89 | 177.22 | 49.26 | Upgrade
|
| Other Long-Term Liabilities | 4.27 | 1.4 | 1.3 | 0.67 | 0.64 | Upgrade
|
| Total Liabilities | 234.11 | 243.1 | 247.04 | 263.59 | 109.92 | Upgrade
|
| Common Stock | 2.09 | 1.87 | 1.4 | 1.34 | 1.33 | Upgrade
|
| Additional Paid-In Capital | 1,106 | 1,065 | 990.66 | 959.61 | 935.71 | Upgrade
|
| Retained Earnings | -1,094 | -1,023 | -909.3 | -743.85 | -585.76 | Upgrade
|
| Comprehensive Income & Other | -1.9 | -3.75 | -0.88 | -11.14 | -10.05 | Upgrade
|
| Shareholders' Equity | 11.85 | 39.51 | 81.88 | 205.96 | 341.23 | Upgrade
|
| Total Liabilities & Equity | 245.96 | 282.62 | 328.92 | 469.55 | 451.14 | Upgrade
|
| Total Debt | 74.21 | 25.24 | 23.08 | 25.47 | 23.71 | Upgrade
|
| Net Cash (Debt) | 77.4 | 121.7 | 181.53 | 344.11 | 344.51 | Upgrade
|
| Net Cash Growth | -36.41% | -32.96% | -47.25% | -0.11% | 437.59% | Upgrade
|
| Net Cash Per Share | 0.31 | 0.61 | 1.13 | 2.21 | 2.42 | Upgrade
|
| Filing Date Shares Outstanding | 257.23 | 246.83 | 165.31 | 156.73 | 155.14 | Upgrade
|
| Total Common Shares Outstanding | 255.94 | 227.17 | 164.52 | 156.26 | 154.79 | Upgrade
|
| Working Capital | 123.64 | 134.76 | 190.87 | 352.92 | 359.08 | Upgrade
|
| Book Value Per Share | 0.05 | 0.17 | 0.50 | 1.32 | 2.20 | Upgrade
|
| Tangible Book Value | 7.97 | 39.18 | 81.44 | 204.96 | 339.5 | Upgrade
|
| Tangible Book Value Per Share | 0.03 | 0.17 | 0.49 | 1.31 | 2.19 | Upgrade
|
| Machinery | 39.91 | 38.97 | 34.92 | 32.65 | 30.52 | Upgrade
|
| Construction In Progress | 0.28 | 0.05 | 28.73 | 5.4 | - | Upgrade
|
| Leasehold Improvements | 43.01 | 57.94 | 28.46 | 28.7 | 28.36 | Upgrade
|
Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.